Picture of Atara Biotherapeutics logo

ATRA Atara Biotherapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Atara Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Atara Biotherapeutics Inc  ATRA.OQ  reported a quarterly
adjusted loss of $3.10​​ per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-17.00.  The mean expectation of five analysts
for the quarter was for a loss of $1.56 per share. Wall Street
expected results to range from $-4.50 to $1.50 per share.
    * Revenue rose 2,892.7% to $28.64 million from a year ago;
analysts expected $39.99 million. 
    * Atara Biotherapeutics Inc's reported EPS for the quarter
was a
loss of $3.10​.
    * The company reported a quarterly loss of $19.05 million.
    * Atara Biotherapeutics Inc shares had fallen by 10.8% this
quarter and lost 40.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 49% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $40.00 
This summary was machine generated from LSEG data August 13 at
01:39 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.56          -3.10          Missed
 Mar. 31 2024      -12.05         -5.75          Beat
 Dec. 31 2023      -12.05         -14.00         Missed
 Sep. 30 2023      -16.55         -16.50         Beat

Recent news on Atara Biotherapeutics

See all news